



September 19, 2016

David Skeen, Deputy Director
Office of International Programs
U.S. Nuclear Regulatory Commission
11555 Rockville Pike
Rockville, Maryland 20852-2738

SUBJECT: Supplement to Application for Approval of Indirect Transfer of Control of Export License No. PXB16.07

Dear Mr. Skeen,

Sterigenics International LLC (“Sterigenics”) hereby supplements the license transfer application, dated August 18, 2016 (the “Application”) requesting U.S. Nuclear Regulatory Commission (“NRC”) approval of an indirect transfer of control of NRC Export License No. PXB16.07 (“the License”), which is held by REVISS Services, Inc. (“the Licensee”). This supplement corrects certain information provided in the Application, which was submitted by Sterigenics’ subsidiary Nordion (Canada) Inc. (“Nordion”) and the Licensee’s present parent company, REVISS Services (UK) Limited. This mistake was inadvertent and is being promptly corrected upon discovery.

In the Application, it was noted that the newly formed entity indirectly acquiring the Licensee, STR 2 BV, would be a wholly-owned subsidiary of Nordion, which, in turn, would be a wholly-owned subsidiary of Sterigenics. *See* Application, Attachment 2, Pre- and Post-Transaction Simplified Organizational Chart. However, Nordion would in fact be a wholly-owned subsidiary of STR 2 BV, which, in turn, would be a nearly wholly-owned subsidiary of Sterigenics.¹ Post-transaction, Nordion and the Licensee would be sister companies, and, as accurately described in the Application, both companies would be subsidiaries of Sterigenics. An updated pre- and post-transaction simplified organizational chart reflecting this information is attached.

No other aspect of the license transfer application has changed, and Sterigenics otherwise affirms the information provided in the Application, including the requested transfer of control. The proposed indirect transfer of control does not involve any amendment to the License and would not result in any changes to the Licensee’s name, organization, NRC-licensed activities, or personnel responsible for such licensed activities. The Licensee will continue to have the same equipment, facilities, personnel and procedures needed to protect public health and safety,

¹ Sterigenics indirectly owns 99.9% of STR 2 BV, while Sterigenics’ immediate parent company, Sterigenics Holdings LLC, owns the remaining 0.1%. As noted in the Application, the entire Sterigenics family, including Nordion and soon to be REVISS, are jointly indirectly owned by two U.S.-based private equity firms, GTCR and Warburg Pincus.

and to secure the licensed material. The License does not need to be amended as a result of the proposed transaction.

If you have any questions or comments pertaining to this transaction, the Application, or this supplement, please contact me, at 847.607.6064 or dlantry@sterigenics.com, or the contacts listed in the Application.

Enclosure: Attachment, Updated Pre- and Post-Transaction Simplified Organizational Chart

cc: Richard Wassenaar, Nordion (Canada) Inc.
John L. Schrader, REVISS Services, Inc.
Ian Latham, REVISS Services (UK) Limited
Nader Mamish, Director, NRC Office of International Programs
Stephen Baker, NRC Office of International Programs
Amy Roma, Hogan Lovells US LLP

I declare under penalty of perjury under the laws of the United States of America that to the best of my knowledge the information contained in the August 18, 2016 Application for Approval of Indirect Transfer of Control of Export License No. PXB16.07, as supplemented in this submittal, is true and correct.

Executed on September 19, 2016.




Daniel Lantry
Senior Vice President and General Counsel
Sterigenics International LLC
3 Parkway North, Suite 100N
Deerfield, IL 60015

Attachment

**UPDATED PRE- AND POST-TRANSACTION
SIMPLIFIED ORGANIZATIONAL CHART**

Updated Simplified Organizational Chart


PRE-TRANSACTION



→ Indicates direct ownership

⋯→ Indicates indirect ownership

POST-TRANSACTION



*Sterigenics International LLC indirectly owns 99.9% of STR 2 BV, while its immediate parent company owns the remaining 0.1%